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Background: HIV-infected patients may be at increased risk of cardiovascular (CV) events, and lipodystrophy is generally
associated with proatherogenic metabolic disturbances. Carotid intima-media thickness (cIMT) has been used as a
surrogate marker for atherosclerosis and it has been shown to be an independent risk factor for CV disease. Our objective
was to evaluate cIMT in HIV-infected patients on combined anti-retroviral therapy (cART) with and without lipodystrophy
defined by fat mass ratio (L-FMR), and to determine the association of lipodystrophy and visceral obesity [(visceral (VAT),
subcutaneous adipose tissue (SAT) volume and VAT/SAT ratio, objectively evaluated by CT scan] with cIMT.
Methods: Cross-sectional study of 199 HIV-infected patients. Body composition by DXA and abdominal CT, lipids, blood
pressure, inflammatory markers, and cIMT by ultrasonography were performed. L-FMR was defined as the ratio of the
percentage of trunk fat mass to the percentage of lower limb fat mass by DXA. Categorical variables were compared
using the chi-square or Fisher’s exact test. Spearman correlation coefficients were estimated to study the association
between cIMT and clinical and metabolic characteristics. Means of cIMT, adjusted for age, were calculated, using
generalized linear models.
Results: L-FMR was present in 41.2% of patients and cIMT was higher in these patients [0.81 (0.24) vs. 0.76 (0.25); p = 0.037)].
Lipodystrophic patients had higher VAT and VAT/SAT ratio and lower SAT. cIMT was associated with lipodystrophy
evaluated by FMR, trunk fat, total abdominal fat, VAT and VAT/SAT ratio. No association was observed between
cIMT and leg fat mass. Using generalized linear models, cIMT means were adjusted for age and no significant
differences remained after this adjustment. The adjusted mean of cIMT was 0.787 (95% CI: 0.751-0.823) in patients
without lipodystrophy, and 0.775 (95% CI: 0.732-0.817) in those with lipodystrophy (p = 0.671).
Conclusions: HIV-infected patients on cART with lipodystrophy defined by FMR, had a significantly higher cIMT.
Carotid IMT was also associated with classical cardiovascular risk factors. In these patients, visceral adipose tissue
had a significant impact on cIMT, although age was the strongest associated factor.
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The development of atherosclerosis lesions is a slow and
progressive process. The use of noninvasive surrogate
markers of atherosclerosis may improve the prognostic
stratification of HIV-infected patients with cardiovascular
risk factors, and also clarify some of the pending issues re-
lated to this disease in HIV infection. Ultrasound is a safe,
inexpensive and rapid technique, which allows an accurate* Correspondence: paula_freitas@sapo.pt
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unless otherwise stated.evaluation of atherosclerosis [1]. Intima-media thickness
(IMT) of the carotid arteries has been used as a surrogate
marker for atherosclerosis and it has been shown to be an
independent risk factor for cardiovascular disease. The role
of age, prolonged survival, traditional and non-traditional
risk factors, direct effect of HIV infection and cART, in re-
lation to surrogate markers of atherosclerosis are under
continuous debate [1]. Thus, due to the long-term survival
associated with cART, harmful effects of the treatment
emerge, as well as a chronic inflammatory state. However,
HIV itself may also promote atherosclerosis by activating
the vascular endothelium directly, or indirectly, byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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of sub-clinical atherosclerosis are seen in HIV-1-infected
patients, and, controversially, these are usually attributed
to classic cardiovascular risk factors and to the side effects
of cART [3-5].
Although the disease can cause alterations in several
metabolic pathways, such as lipid and glucose metabol-
ism, lipodystrophic patients, per se, may also be at a
higher risk of atherosclerosis, as fat redistribution is
associated with the presence of several known meta-
bolic risk factors for cardiovascular diseases [6]. Fur-
thermore, patients with clinical lipodystrophy have a
significantly higher risk of coronary heart disease at
10 years, measured by the Framingham risk score, than
patients without clinical lipodystrophy and those with
clinical lipodystrophy and metabolic syndrome were
more often classified in moderate and high risk cat-
egories, than those without metabolic syndrome [7].
The objectives of this study were to evaluate cIMT in
HIV-infected patients subject to cART, according to the
presence of lipodystrophy, as objectively defined by
FMR, and also to evaluate the association of lipodystro-
phy, visceral obesity [(visceral (VAT), subcutaneous adi-
pose tissue volume (SAT) and VAT/SAT ratio objectively
evaluated by CT scan] and other established cardiovascu-
lar risk factors, with cIMT.Methods
Subjects
As part of a cross-sectional study, clinically stable, HIV-
infected, non-institutionalized Caucasian adults who were
receiving antiretroviral therapy were evaluated. These
were all referred from the Infectious Diseases Outpatient
Clinic and only patients subject to cART were included.
This study was approved by the Ethics Committee for
Health of the Hospital São João in Porto and each patient
agreed to provide written, informed consent.Clinical assessment
For each patient, the following information was collected,
using a standardized protocol: age, gender, known dur-
ation of HIV infection and duration of cART exposure,
HIV risk factor, characterization of the infection, smoking
history (past, current, or never), family history of CV dis-
eases, and use of anti-hypertensive, anti-diabetic, or lipid
lowering drugs.
We used the “Centers for Disease Control and Preven-
tion” (CDC) HIV staging classification [8]. Weight, height,
circumferences of neck, waist, hip, thigh and arm were
measured, as previously described [9]. All measurements
were performed by the same observer, using standard
techniques [10].Resting blood pressure (BP) taken whilst in a supine
position was measured in a standardized fashion, as previ-
ously described [7].Evaluation of body composition
Body composition was assessed with whole-body, dual-
energy X-ray absorptiometry (DXA) (DXA – Lunar Ex-
pert XL, 1999). DXA measurements were performed
while the patient was in a supine position, with stand-
ard positioning of the arms and feet. Markers for the
trunk and lower limbs that defined regions of interest
were defined in accordance with the manufacturer’s in-
structions. Regional fat mass values were grouped and
analyzed for the following anatomical regions: arms,
legs, trunk and total body. The fat mass ratio (FMR)
was calculated as the ratio between the percentage of
trunk fat mass and the percentage of lower limb fat
mass (FMR =% of the trunk fat mass/% of the lower
limb fat mass) [11]. We used a cut-off value for lipody-
strophy defined by FMR for men of 1.961, and 1.329
for women [12].
The quantification of total, visceral, and subcutaneous
fat was performed with a 64-slice, abdominal computed
tomography (CT) scanner (Siemens Sensation 64 Cardiac),
with the same technique as previously described [13,14].
All values were expressed in cm2, rounded to the nearest
centesimal.Laboratory analysis
Biological and inflammatory parameters:
A venous blood sample was taken after a 12-hour
overnight fast. All the samples were analyzed at the
central laboratory of our hospital. The measurements
of total cholesterol (TC), low density lipoprotein (LDL)
cholesterol, high-density lipoprotein (HDL) cholesterol,
triglycerides, apolipoprotein A1 (apo A1), apolipopro-
tein B (apo B), lipoprotein (a) [Lp (a)], fibrinogen, high
sensitivity C-reactive protein (hsCRP), homocysteine,
uric acid, lactates, NT-proBNP, glucose, insulin and A1c
serum levels were determined using commercial kits.
Non HDL-C was defined as TC-HDL. Microalbumi-
nuria was determined in a 24 hour urine sample. Pa-
tients without a previous diagnosis of diabetes were
submitted to an oral glucose tolerance test (OGTT).
This test was performed as instructed by the World
Health Organization [15].
The CD4+ cell count (×106 cell/L) was determined
by flow cytometry and plasma HIV-1 RNA loads were
measured by a quantitative reverse transcriptase poly-
merase chain reaction (Roche Diagnostic Systems, Inc.,
Branchburg, NJ, USA), which had a lower limit of de-
tection of 50 copies/mL.
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Insulin resistance was defined by the homeostasis model
assessment of insulin resistance (HOMA), using the fol-
lowing formula:
HOMA ‐ IR index = (insulin 0 x glucose 0)/22.5 [16].
Carotid IMT measurement
High-resolution B-mode and Doppler ultrasonography of
the carotid arteries was carried out with a Philips iU22
machine (Philips Medical, The Netherlands), equipped
with a 17–5 MHz high-frequency linear-array transducer.
Patients were examined in the supine position, with the
head in a neutral position, or slightly turned away from
the side that was being scanned. The left and right com-
mon carotid arteries (CCA) were examined in multiple di-
rections and measurements were performed using the
images with the best wall definition. IMT was measured
3 cm below the carotid bulb in a longitudinal image. Three
measurements were obtained on each side, and the mean
IMT of these values was calculated. All studies were per-
formed by the same radiologist, who had 12 years of ex-
perience in vascular ultrasound, and were carried out
using the same machine.
The presence of subclinical carotid atherosclerosis was
defined as IMT > 0.80 mm (70th percentile of the IMT
distribution), presence of plaque, or both [17-19].
Statistical analysis
Data was described as mean and standard deviation
(SD) for quantitative variables, and was compared using
Student-t or Mann–Whitney tests, as appropriate. Cat-
egorical variables were described as counts and propor-
tions, and compared using the chi-square or Fisher’s exact
test. To study the association between cIMT and clinical
and metabolic characteristics, Spearman correlation coeffi-
cients were estimated. Means of cIMT, adjusted for age,
were calculated, using generalized linear models.
Statistical analysis was performed using SPSS version
17.0 software (SPSS Inc., Chicago, Illinois, USA). All




In this sample of 199 HIV-1 infected patients (132 men
and 67 women) on cART, 41.2% presented lipodystrophy
defined by FMR. Table 1 shows the characteristics of the
study sample, according to the presence of lipodystrophy
defined by FMR.
Patients with lipodystrophy were older, had been in-
fected with HIV for a longer time and had a greater length
of cART. No differences in weight, height, BMI, waist and
arm circumferences among patients with, or without lipo-
dystrophy, were observed. Patients with lipodystrophy hadlower hip and thigh circumferences, but higher neck cir-
cumference and a higher waist/hip circumference ratio
than those without lipodystrophy. Furthermore, patients
with lipodystrophy had a higher systolic blood pressure
and leukocyte count and a mean CD4+ cell count.
No differences were observed between patients with,
and without, lipodystrophy regarding viral suppression
rate, HIV risk factor, CDC classification and ART regi-
mens, smoking history, family history of CV disease and
medication history (statins, fibrates, oral anti-diabetics,
insulin and anti-hypertension drugs).
Body composition by DXA
In the evaluation of body composition by DXA, patients
with lipodystrophy had a lower total, leg and arm fat mass,
both in terms of % and Kg. No difference was observed in
trunk fat mass (in % and Kg) between the two groups.
Patients with lipodystrophy had a higher VAT and
VAT/SAT ratio, lower SAT and no significant difference
in total fat at abdominal level.
Metabolic parameters
Patients with lipodystrophy had higher glucose and insulin
at 0 minutes, and insulin at 120 minutes on OGTT,
HOMA, non-HDL cholesterol, triglycerides, uric acid, and
lactates, than patients without lipodystrophy. No significant
differences were found in the 2-hour value of glucose on
OGTT, total cholesterol, LDL-cholesterol, HDL-cholesterol,
apo A1, apo B, ratio Apo B/Apo A1, Lp(a), homocysteine,
CRP, hsCRP, NT-ProBNP, fibrinogen and microalbumin
urinary excretion between the two groups.Carotid IMT measurements
Carotid IMT was higher in patients with lipodystrophy,
than in patients without lipodystrophy [mean (SD) 0.81
(0.24) vs. 0.76 (0.25); p = 0.037)] (Figure 1).
Carotid IMT correlated positively with lipodystrophy
evaluated by FMR, age, waist/hip ratio, neck circumfer-
ence, trunk fat mass evaluated by DXA, visceral obesity
defined by total abdominal fat, VAT and VAT/SAT ratio,
systolic blood pressure, glucose at 0 and 120 minutes on
OGTT, A1c, non-HDL cholesterol, uric acid, CRP, hsCRP
and homocysteine. No significant correlations were found
between IMT and duration of HIV infection, length of
cART, thigh circumference, total, leg and arm fat mass
evaluated by DXA, CD4 cell count, leukocyte, insulin at 0
and 120 minutes on OGTT, HOMA, triglycerides, and
lactates (Table 2).
Using generalized linear models, cIMT means were ad-
justed for age, and no significant differences remained
after this adjustment when patients with, and without,
lipodystrophy were compared. The age adjusted mean of
cIMT was 0.787 (95%CI: 0.751-0.823) in patients without
Table 1 Sample characteristics according to the presence of lipodystrophy defined by FMR
Without L With L P
n (%) 117 82 -
Gender [n (%)]
Male 71 (60.7) 61 (74.4) 0.063
Female 46 (39.3) 21 (25.6)
Age [years, mean (sd)] 44.8 (12.1) 49.2 (10.2) 0.002
Duration of HIV infection [years, mean (sd)] 7.2 (3.8) 8.5 (3.5) 0.005
cART [years, mean (sd)] 5.7 (3.7) 7.9 (3.3) <0.001
Weight [Kg, mean (sd)] 68.0 (14.3) 68.0 (10.6) 0.805
Height [m, mean (sd)] 1.64 (0.09) 1.64 (0.08) 0.518
BMI [(Kg/m2), mean (sd)] 25.2 (5.0) 25.3 (4.0) 0.637
Waist circumference [cm, mean (sd)] 90.6 (12.7) 92.6 (10.2) 0.174
Hip circumference [cm, mean (sd)] 96.1 (9.4) 92.5 (6.4) 0.005
Thigh circumference [cm, mean (sd)] 48.5 (5.5) 47.0 (4.9) 0.025
Arm circumference [cm, mean (sd)] 26.7 (3.2) 27.2 (2.6) 0.285
Neck circumference [cm, mean (sd)] 36.6 (3.8) 37.8 (3.8) 0.045
Waist/hip circumference ratio [mean (sd)] 0.94 (0.09) 1.00 (0.07) <0.001
CD4 cell count [cells/mm3, mean (sd)] 502.7 (265.0) 631.8 (340.8) 0.006
HIV RNA (<50) [n (%)] 102 (87.2) 74 (90.2) 0.660
HIV risk factor [n (%)]
Injecting drug user 32 (27.8) 15 (18.3) 0.050
Homosexual contact 7 (6.1) 14 (17.1)
Heterosexual contact 74 (64.3) 51 (62.2)
Others 2 (1.7) 2 (2.4)
CDC [n (%)]
A 63 (54.3) 53 (64.6) 0.209
B 1 (0.9) 0 (0)
C 52 (44.8) 29 (35.4)
ART [n (%)]
PI 59 (51.3) 48 (58.5) 0.390
NNRTI 58 (50.4) 38 (46.3) 0.673
NRTI 112 (97.4) 79 (96.3) 0.695
Smoking history [n (%)]
Never 44 (37.9) 36 (43.9)
Current 55 (47.4) 27 (32.9)
Former 17 (14.7) 19 (23.2) 0.092
Familial history of CVD [n (%)] 51 (43.6) 40 (48.8) 0.563
Taking medications [n (%)]
Statins 22 (19.0) 25 (30.5) 0.088
Fibrates 39 (33.6) 39 (47.6) 0.067
Oral anti-diabetics 13 (11.2) 16 (19.5) 0.154
Insulin 6 (5.2) 4 (4.9) 1.000
Anti-hypertensive drugs 21 (17.9) 19 (23.5) 0.442
Fat mass [%, mean (sd)] DXA
Total 24.8 (13.1) 19.3 (8.5) 0.003
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Table 1 Sample characteristics according to the presence of lipodystrophy defined by FMR (Continued)
Trunk 25.7 (13.3) 24.3 (9.0) 0.446
Leg 24.4 (14.7) 11.1 (7.4) <0.001
Arm 27.2 (17.1) 20.3 (13.6) 0.007
Fat mass [Kg, mean (sd)] DXA
Total 17.3 (11.1) 13.2 (7.3) 0.013
Trunk 9.3 (6.0) 9.0 (4.8) 0.918
Leg 5.2 (3.6) 2.1 (1.6) <0.001
Arm 2.1 (1.9) 1.5 (1.2) 0.019
Body fat mass by quantitative CT
Total fat [cm2, mean (sd)] 282.2 (174.5) 276.6 (124.0) 0.865
VAT [cm2, mean (sd)] 111.5 (85.8) 158.2 (63.2) <0.001
SAT [cm2, mean (sd)] 170.8 (125.7) 118.3 (93.1) 0.002
VAT/SAT ratio [cm2, mean (sd)] 1.08 (1.46) 2.43 (2.62) <0.001
Systolic blood pressure [mmHg, mean (sd)] 120.0 (18.9) 124.6 (15.8) 0.039
Diastolic blood pressure [mmHg, mean (sd)] 75.8 (11.9) 78.0 (10.6) 0.139
Leukocytes [109/L, mean (sd)] 5.66 (1.67) 6.39 (1.88) 0.007
Glucose 0 min [mg/dL, mean (sd)] 104.4 (45.1) 114.7 (44.2) 0.003
Glucose 2 hours [mg/dL, mean (sd)] 123.6 (42.9) 139.2 (50.3) 0.051
Insulin 0 min [μU/mL, mean (sd)] 9,49 (10.28) 13.00 (10.68) 0.002
Insulin 2 hours [μU/mL, mean (sd)] 52.43 (46.65) 91.32 (147,24) 0.007
HOMA [mean (sd)] 2,54 (2.90) 3.73 (3.31) <0.001
A1c [% mean (sd)] 5.50 (1.06) 5.77 (0.06) 0.001
Total cholesterol [mg/dL, mean (sd)] 218.6 (53.2) 233.6 (61.0) 0.093
LDL-cholesterol [mg/dL, mean (sd)] 126.1 (47.1) 132.3 (50.7) 0.461
HDL-cholesterol [mg/dL, mean (sd)] 47.0 (14.4) 44.3 (12.0) 0.262
Non-HDL cholesterol [mg/dL, mean (sd)] 171.6 (48.9) 189.3 (56.5) 0.019
Triglycerides[mg/dL, mean (sd)] 247.5 (170.9) 307.2 (198.5) 0.006
Apo A1 [mg/dL, mean (sd)] 118.8 (25.8) 114.3 (18.3) 0.204
Apo B [mg/dL, mean (sd)] 104.7 (26.7) 106.1 (25.4) 0.827
Ratio apo B/apo A1 [mean (sd)] 0.91 (0.27) 0.95 (0.25) 0.297
Lp (a) [mg/dL, mean (sd)] 30.2 (31.2) 31.1 (39.7) 0.421
Homocysteine [μmol/L, mean (sd)] 9.6 (4.1) 9.8 (3.7) 0.435
CRP [mg/L, mean (sd)] 5.4 (12.9) 4.0 (4.2) 0.913
hsCRP [mg/dL, mean (sd)] 0.48 (0.91) 0.37 (0.28) 0.185
Lactates [mmol/L, mean (sd)] 1.12 (0.47) 1.36 (0.58) 0.001
NT-ProBNP [pg/mL, mean (sd)] 39.1 (67.3) 28.6 (27.1) 0.414
Fibrinogen [mg/dL, mean (sd)] 344.8 (98.3) 336.2 (92.1) 0.463
Microalbumin [mg/L, mean (sd)] 49.1 (150.6) 26.0 (67.7) 0.435
Uric acid [mg/L, mean (sd)] 44.4 (15.2) 51.2 (15.4) <0.001
Carotid IMT [mm, mean (sd)] 0.76 (0.25) 0.81 (0.24) 0.037
(L – Lipodystrophy FMR defined; CDC – Centers for Disease Control and Prevention criteria for staging of HIV infection; cART – combined antiretroviral therapy;
BMI – body mass index; FMR – fat mass ratio; CVD – cardiovascular disease; DXA – dual-energy X-ray absorptiometry; CT – computed tomography;
PI – protease inhibitor; NNRTI – non-nucleoside reverse transcriptase inhibitor; NRTI – nucleoside reverse transcriptase inhibitor, VAT – visceral adipose tissue,
SAT – subcutaneous adipose tissue, IMT – intima-media thickness).
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Figure 1 Mean differences of carotid IMT by the presence of
lipodystrophy defined by FMR.
Table 2 Correlations between cIMT and body
composition and metabolic parameters
Correlations between cIMT and R P
Age 0.709 <0.001
Duration of HIV infection −0.019 0.779
cART 0.024 0.727
Waist/hip ratio 0.387 <0.001
Thigh circumference −0.095 0.169
Neck circumference 0.202 0.007
CD4 cell count −0.027 0.701
Systolic blood pressure 0.419 <0.001
Leukocytes −0.049 0.478
Glucose 0 min 0.284 <0.001
Glucose 2 hours OGTT 0.220 0.006
Insulin 0 min 0.026 0.711
Insulin 2 hours OGTT −0.089 0.271
HOMA 0.094 0.185
A1c 0.285 <0.001
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with lipodystrophy (p = 0.671).Triglycerides 0.109 0.113




Uric acid 0.146 0.034
Lactates 0.081 0.253




Total fat on abdominal CT scan 0.218 0.002
VAT on abdominal CT scan 0.418 <0.001
SAT on abdominal CT scan −0.009 0.901
VAT/SAT ratio on abdominal CT scan 0.290 <0.001
FMR 0.250 p < 0.001
(IMT – intima-media thickness; cART – combined antiretroviral therapy;
CDC – Centers for Disease Control and Prevention criteria for staging of HIV
infection; cART – combined antiretroviral therapy; OGTT – oral glucose
tolerance test; HOMA – the homeostasis model assessment of insulin
resistance; HDL-high density cholesterol; CPR –C protein reactive; VAT – visceral
adipose tissue; SAT – subcutaneous adipose tissue; CT – computed tomography;
FMR – fat mass ratio).
p = 0.037.Discussion
Our aim was to evaluate the association between object-
ively defined lipodystrophy and cIMT. Prior studies that
had evaluated the effect of lipodystrophy on cIMT, had
conflicting results [20-22]. We found that cIMT was
higher in patients with lipodystrophy defined by FMR,
than in patients without lipodystrophy [0.81 (0.24) vs.
0.76 (0.25); p = 0.037)]. Coll et al. showed that the pres-
ence of lipodystrophy defined by clinical parameters in-
creased by 3-fold the risk of sub-clinical carotid
atherosclerosis in patients with HIV-infection [21]. On
the other hand, Mercié et al. showed a significant asso-
ciation between cIMT and lipodystrophy in a univariate
analysis, but the effect disappeared in the multivariate
model [20]. Coll et al. suggested that this discrepancy of
results was due to the younger and healthier population
of the latter, since the mean cIMT was 0.54 mm (range
0.50-0.60), while in the Coll’s samples, the mean cIMT
was 0.80 (range 0.40-1.80). In Coll’s study, the mean age
of the patients with lipodystrophy was 42.38 (1.09) years
while in Mercié’s it was 43.7 (8.3) years. The mean age
of Coll’s patients without lipodystrophy was 40.59
(0.75), while in the Mercié et al’s study, it was 39.4 (8.7)
years. Our patients, either with lipodystrophy [49.2 (10.2)
years], or without lipodystrophy [44.8 (12.1) years], were
older than those of these previous published studies. Des-
pite being older than those of Coll et al., our patients had
a mean cIMT identical to Coll’s patients [with lipodystro-
phy cIMT 0.88 (0.04) vs. without lipodystrophy 0.76 (0.02)
mm; p = 0.007], but similar to Mercié’s study, no signifi-
cant differences remained after adjustment for age.Visceral obesity is another independent risk factor for
CVD in the background population [23] and independent
associations of obesity and abdominal adiposity with cIMT
were observed [24]. We also found that cIMT was posi-
tively correlated with waist/hip ratio, neck circumference,
and trunk fat mass evaluated by DXA and visceral obesity
defined by total abdominal fat, VAT and VAT/SAT ratio
by CT scan. However, the mechanisms by which obesity is
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lished, even though the role of metabolic factors, such as
insulin resistance and altered plasma adiponectin levels,
has been proposed. Yet body composition and fat distribu-
tion may influence systemic hemodynamics - both sys-
temic blood pressure and total blood volume [25].
Insulin resistance has been independently associated
with vascular disease and accelerated CV disease in
HIV-infected adults [26]. In our sample, patients with
lipodystrophy had higher glucose and insulin at 0 and
120 minutes on OGTT, and greater HOMA than pa-
tients without lipodystrophy. Carotid IMT correlated
positively with glucose at 0 and at 120 minutes on OGTT
and A1c. Despite the higher insulin resistance evaluated
by HOMA, no significant correlations were observed be-
tween cIMTand HOMA.
Some studies have demonstrated that traditional CV risk
factors overshadow the role of HIV infection and/or
cART, and that they are the major determinants of cIMT
progression [4,27-30]. Sankatsing et al. have shown that
HIV infection and/or cART were associated with in-
creased cIMT independent of traditional CV risk factors
[31], and Lekakis et al. pointed to the combination of all
parameters [32]. Older age is a traditional CV risk factor,
associated with higher mean cIMT and a higher preva-
lence of carotid lesions [30,33]. We also found that cIMT
correlated positively with age. As with Mercié’s study,
cIMT was significantly associated with age and also with
waist- to-hip ratio, systolic BP, non-HDL cholesterol, glu-
cose disorders and homocysteine.
Adverse lipid and metabolic changes associated with
HIV infection or cART exposure may be important pro-
inflammatory factors [34], and plasma lipid alterations
have been associated with an increased cIMT [35]. We
found that cIMT was positively correlated with non-
HDL cholesterol and was also positively correlated with
systolic blood pressure. Similar to Mercié et al., we also
observed an association between total plasma homo-
cysteine and cIMT in HIV-infected patients subject to
cART, as was previously demonstrated in non-infected
patients [20].
It should be noted that certain “classical” vascular risk
factors are over-represented in the HIV-infected popula-
tion, e.g. smoking. However, we observed no differences
between patients with, and without, lipodystrophy, with
regards to smoking history. Also, no differences were ob-
served between patients with, and without, lipodystrophy,
with regards to viral suppression rate, HIV risk factor,
CDC classification and ART regimens, family history of
cardiovascular disease, and also medications taken (oral
anti-diabetic drugs, insulin and anti-hypertension drugs).
Statins are known to have beneficial effects on the arterial
wall [36], but, once again, no differences were observed
with those taking statins and fibrates.In HIV-negative patients, both leukocyte count and
CRP and hsCRP have been linked to endothelial dys-
function and future CV events [37,38]. Similar to Hsue,
we found that hsCRP was associated with cIMT. How-
ever, in Hsue’s study, after adjusting for all traditional
risk factors, the association between hsCRP and cIMT
was no longer significant [39].
Study limitations
The limitations of this study are mainly related to the obser-
vational design and the cross-sectional nature of our ana-
lyses, which preclude any conclusions regarding causality.
Subclinical atherosclerosis evaluated by carotid IMT, reflects
the cumulative effects of risk factors acting over many years,
whereas we measured risk factors at only one point in time.
Thus, blood lipid concentrations, blood pressure, smoking
habits and other CV risks estimated at one point in time,
may not accurately represent lifetime exposure. On the
other hand, we only used a qualitative assessment of smok-
ing habits and not a quantitative one. Moreover, cART,
CD4 +T-cell count, HIV viral load, and CVD risk mediators
are dynamic variables which change over time.
Some aspects of our study need to be highlighted.
Firstly, we only used objective methods for the evaluation
of body composition: the presence of lipodystrophy was
defined by FMR by DXA and visceral obesity by a CT
scan. Secondly, this is one of the first reports in which
cIMT was used as an outcome. And thirdly, we emphasize
that increased cIMT could be a predictor of clinical car-
diovascular endpoints, namely, coronary and cerebrovas-
cular ones [18].
Conclusions
HIV-infected patients under cART with FMR defined
lipodystrophy had a significantly higher cIMT when
compared with patients without lipodystrophy. Carotid
IMT in a univariate analyses was positively associated
with lipodystrophy defined by FMR, VAT, VAT/SAT ra-
tio, age and other classical cardiovascular risk factors.
Visceral adipose tissue had an impact on cIMT in HIV-
patients subject to cART, but no significant associations
remained when this was adjusted for age.
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